BioWorld

Aug. 8, 2005

Anadys Raises $62M To Advance Early Programs

Two months ago, when Anadys Pharmaceuticals Inc. signed what might be the largest Phase I deal in biotech history, the company's CEO said Anadys wouldn't need to do a financing for at least two years. (BioWorld Today) Read More

Neose Reduces Work Force 25 Percent In Restructuring

FDA Raises Drug Application Costs For Coming Fiscal Year

Advanced Life Sciences Gets $32M In Lethargic IPO Market

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 10, 2025.

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Red blood cells in an artery with cholesterol

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

BioWorld

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...

Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...